Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs

American Journal of Veterinary Research

Volumn 58, Issue 8, 1997, Pages 857-863

  Gamblin, Rance M ^a   Sagartz, John E ^a   Couto, C Guillermo ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTEIN P53;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; CARCINOMA; DERMATOFIBROMA; DOG; DOG DISEASE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; NEOPLASM; PATHOLOGY; RABBIT; RETROSPECTIVE STUDY; SARCOMA;

ANIMALS; ANTIBODIES; CARCINOMA; DOG DISEASES; DOGS; HISTIOCYTOMA, BENIGN FIBROUS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MAST-CELL SARCOMA; NEOPLASMS; RABBITS; RETROSPECTIVE STUDIES; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031203589     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Perkins AS, Vande Woude GF. Principles of molecular cell biology of cancer: oncogenes. In : DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Co, 1993;35-56.
2. Caron de Fromentel C, Soussi T. The p53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
3. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
4. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-680.
5. Ginsberg D, Mechta F, Yaniv M, et al. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 1991;88:9979-9983.
6. Santanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991;88:7605-7609.
7. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
8. Maxwell SA, Roth JA. Binding of cellular proteins to a conformational domain of tumor suppressor protein p53. Oncogene 1993;8:3421-3426.
9. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
10. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
11. Clarke AR, Purdie CA, Harrision DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
12. Hermeking H, Eick D. Mediation of c-myc-induced apoptosis by p53. Science 1994;265:2091-2093.
13. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-967.
14. Elledge RM. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 1996;88:141-143.
15. Chin K, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-462.
16. Hall PA, Ray A, Lemoine NR, et al. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology (letter). Lancet 1991;338:513.
17. Baas IO, Mulder JWR, Offerhaus JA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:13-18.
18. Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-1602.
19. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-679.
20. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-1327.
21. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-330.
22. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?-revisited! J Pathol 1994;172:1-4.
23. Esrig D, Spruck CH, Nichols PW, et al. p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397.
24. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
25. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-435.
26. Mayr B, Heczko U, Schellander K, et al. Sequence of an exon of the feline p53 gene-mutation in a lymphosarcoma. Br Vet J 1993;149:387-390.
27. Okuda M, Umeda A, Matsumoto Y, et al. Molecular cloning and chromosomal mapping of feline p53 tumor suppressor gene. J Vet Med Sci 1993;55:801-805.
28. Okuda M, Umeda A, Sakai T, et al. Cloning of feline p53 tumor suppressor gene and us aberration in hematopoietic tumors. Int J Cancer 1994;58:602-607.
29. Develilee P, Van Leeuwen IS, Voesten A, et al. The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 1994;14:2039-2046.
30. Mayr B, Schellander K, Schleger W, et al. Sequence of an exon of the canine p53 gene-mutation in a papilloma. Br Vet J 1994; 150:81-84.
31. Mayr B, Schaffner G, Kurzbauer R, et al. Sequence of an exon of tumor suppressor p53 gene - a comparative study in domestic animals: mutation in a feline solid mammary carcinoma. Br Vet J 1995;151:325-329.
32. Kraegel SA, Pazzi KA, Madewell BR. Sequence analysis of canine p53 in the region of exons 3-8. Cancer Lett 1995;92:181-186.
33. Sagartz JE, Bodley WL, Gamblin RM, et al. p53 tumor suppressor gene overexpression in osteogenic tumors of dogs. Vet Pathol 1996;33:213-221.
34. Prioleau J, Schnitt SJ. p53 antigen loss in stored paraffin slides. N Engl J Med 1995;332:1521-1522.
35. Kato J, Sakamaki S, Niitsu Y. More on p53 antigen loss instored paraffin slides. N Engl J Med 1995;333:1507-1508.
36. Andreassen A, Oyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993;53:468-471.
37. Ueda Y, Dockhorn-Dwornicazk B, Balsius S, et al. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993;119:172-178.
38. Sheridan E, Silcocks P, Smith J, et al. p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur J Cancer 1994;30A:1701-1704.
39. Ludlow JW. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 1993;7: 866-871.
40. Moran E. Interaction of adenoviral proteins with pRB and p53. FASEB J 1993;7:880-885.
41. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
42. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation of p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8: 531-539.
43. Monand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
44. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
45. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-749.
46. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-392.
47. Piris MA, Pezella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994;69:337-341.
48. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-1227.
49. MacEwen EG. Miscellaneous tumors. A. Hemangiosarcoma. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 2nd ed. Philadelphia: WB Saunders Co, 1996;521-529.
50. Frank JL, Bur ME, Garb JE, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-186.
51. Urbach F. Geographic distribution of skin cancer. J Surg Cncol 1971;3:219-234.
52. Dorn CR, Taylor D, Schneider R. Sunlight exposure and the risk of developing cutaneous and oral squamous cell carcinoma in white cats. J Natl Cancer Inst 1971;46:1073-1078.
53. Madewell BR, Conroy JD, Hodgkins EM. Sunlight skin cancer association in the dog: a report of 3 cases. J Cutan Pathol 1981;8: 434-443.
54. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-1703.
55. Starzynska T, Markiewski M, Domagala W, et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-2012.
56. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
57. Hongyo T, Buzard GS, Calvert RJ, et al. 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 1993;21: 3637-3642.
58. Sun XF, Carstensen JM, Zhang H, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-1373.
59. Bosari S, Viale G, Bossi P, et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinoma. J Natl Cancer Inst 1994;86:681-687.
60. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-7266.
61. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-798.
62. Barnes DM, Dublin EA, Fisher CJ, et al. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-476.
63. MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 2nd ed. Philadelphia: WB Saunders Co, 1996;451-479.
64. Appelbaum FR, Sale GE, Storb R, et al. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. Hematol Oncol 1984;2:151-168.
65. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphoma in dogs: a morphologic, immunologic, and clinical study. Cancer 1990;66:480-490.
66. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
67. Vail DM, Withrow SJ. Tumors of the skin and subcutaneous tissues. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 2nd ed. Philadelphia: WB Saunders Co, 1996;167-191.
68. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-182.
69. Elledge RM, Clark GM, Fuqua SAW, et al. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 1994;54:3752-3757.